NIKKEI 225
38,412.82 +860.66 (+2.29%) HANG SENG
17,090.20 +261.27 (+1.55%) CRUDE OIL
83.44 +0.08 (+0.10%) GOLD FUTURES
2,340.40 -1.70 (-0.07%) DOW
38,503.69 +263.71 (+0.69%) Bitcoin GBP
53,500.51 +79.00 (+0.15%)
Novartis AG (0QLR.IL)
| Previous close | 86.12 |
| Open | 0.00 |
| Bid | 87.35 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 1,943,484 |
| Market cap | 205.406B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 27.91 |
| EPS (TTM) | 3.21 |
| Earnings date | N/A |
| Forward dividend & yield | 3.20 (3.78%) |
| Ex-dividend date | 09 Mar 2023 |
| 1y target est | N/A |
- Yahoo Finance Video
Novartis raises full-year guidance on Q1 beat, drug sales
Shares of Novartis (NVS) are soaring in Tuesday's pre-market trading session — holding onto steady gains into the market open — after the Swiss pharmaceutical giant reported better-than-expected first-quarter earnings and raised its full-year guidance. The robust financial performance was driven primarily by strong sales of the company's innovative heart failure and psoriasis treatment drugs. Yahoo Finance Health Reporter Anjalee Khemlani breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Angel Smith
BenzingaFDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
Tuesday, Novartis AG (NYSE:NVS) received FDA approval for its Lutathera (lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for pediatric patients 12 years and older with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs. This approval makes Lutathera the first therapy specifically reviewed and approved for use in pediatric patients with GEP-NETs. Related: Novartis Stock Gains On European Drugm
Investor's Business DailyHow Novartis Rode Two Blockbuster Drugs To Its Beat And Raise, And Three-Day Sprint
Novartis stock jumped Tuesday after the drugmaker topped first-quarter sales and earnings forecasts, and raised its full-year outlook.
